VALINE

US Previously Marketed

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C5H11NO2
Molecular Weight	117.1463
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)[C@H](N)C(O)=O

InChI

InChIKey=KZSNJWFQEVHDMF-BYPYZUCNSA-N

InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C5H11NO2
Molecular Weight	117.1463
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB00161
Curator's Comment: description was created based on several sources, including http://medical-dictionary.thefreedictionary.com/valine

Valine is an α-amino acid that is used in the biosynthesis of proteins. It is essential in humans, meaning the body cannot synthesize it and thus it must be obtained from the diet. There is a mixed scientivic evidence that as a dietary supplement valine improves training efficacy, delays central fatigue.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
tryptophan transport 1 Target ID: GO:0015827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16424144	Inhibitor 8504

Conditions

Condition	Modality	Targets	Highest Phase	Product
Burns 17 Sources: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=016822	Primary		Approved 8583	FREAMINE III 10% Approved Use Parenteral nutrition with 8.5% FreAmine® III (Amino Acid Injection) with Electrolytes is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients, where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. Dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance Launch Date 1971
Central fatigue 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26785372	Preventing		Natural Metabolite	Unknown Approved Use There is a mixed scientivic evidence that as a dietary supplement valine improves training efficacy, delays central fatigue.

C_max

Value	Dose	Co-administered	Analyte	Population
12.36 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
40.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.42 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/26119505/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:		VALINE plasma	Canis lupus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:27266	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:27266
ChemicalBook	CB5312867	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5312867
eMolecules	514157	https://www.emolecules.com/cgi-bin/more?vid=514157
MolPort	MolPort-039-060-192	https://www.molport.com/shop/molecule-link/MolPort-039-060-192

PubMed

Title	Date	PubMed
An algorithm for mapping positively selected members of quasispecies-type viruses.	2001	11265061
Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN69 dialysis membranes.	2001	11174010
Multiple transport pathways for dibasic amino acids in the larval midgut of the silkworm Bombyx mori.	2001 Apr 27	11267901
The valine-to-threonine 75 substitution in human immunodeficiency virus type 1 reverse transcriptase and its relation with stavudine resistance.	2001 Apr 27	11134027
Effect of polymorphisms on ligand binding by mouse major urinary proteins.	2001 Feb	11266626
Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats.	2001 Feb	11230314
Comparison of in vitro systems of protein digestion using either mammal or fish proteolytic enzymes.	2001 Feb	11223397
Do ACE inhibitors or ARBs limit restenosis after stenting? --assimilating the data.	2001 Feb	11176016
Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial.	2001 Feb	11176015
Design, X-ray crystallography, molecular modelling and thermal stability studies of mutant enzymes at site 172 of 3-isopropylmalate dehydrogenase from Thermus thermophilus.	2001 Feb	11173468
The effect of amino acid spacers on the antigenicity of dimeric peptide--inducing cross-reacting antibodies to a cell surface protein antigen of Streptococcus mutans.	2001 Feb	11169138
A molecular variant of the APC gene at codon 1822: its association with diet, lifestyle, and risk of colon cancer.	2001 Feb 1	11221825
C677T variant form at the MTHFR gene and CL/P: a risk factor for mothers?	2001 Feb 1	11170082
Angiotensin II type 1 receptor blockers.	2001 Feb 13	11171802
A 7-kDa prion protein (PrP) fragment, an integral component of the PrP region required for infectivity, is the major amyloid protein in Gerstmann-Sträussler-Scheinker disease A117V.	2001 Feb 23	11087738
The dimerization motif of cytosolic sulfotransferases.	2001 Feb 9	11172807
Critical role of the residue size at position 87 in H2O2- dependent substrate hydroxylation activity and H2O2 inactivation of cytochrome P450BM-3.	2001 Feb 9	11162663
Construction and physiological studies on a stable bioengineered strain of shengjimycin.	2001 Jan	11269716
Valine 77 of heterocystous ferredoxin FdxH2 in Anabaena variabilis strain ATCC 29413 is critical for its oxygen sensitivity.	2001 Jan	11269658
Reduction of wobble-position GC bases in Corynebacteria genes and enhancement of PCR and heterologous expression.	2001 Jan	11200224
Herpetic folliculitis and syringitis simulating acne excoriée.	2001 Jan	11176676
V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression.	2001 Jan	11164181
Genetic and biochemical analyses of a eukaryotic-like phospholipase D of Pseudomonas aeruginosa suggest horizontal acquisition and a role for persistence in a chronic pulmonary infection model.	2001 Jan	11136451
The distinct disease phenotypes of the common and yellow vein strains of Tomato golden mosaic virus are determined by nucleotide differences in the 3'-terminal region of the gene encoding the movement protein.	2001 Jan	11125157
The V410M mutation associated with pyrethroid resistance in Heliothis virescens reduces the pyrethroid sensitivity of house fly sodium channels expressed in Xenopus oocytes.	2001 Jan	11102831
A (13)C NMR study on [3-(13)C]-, [1-(13)C]Ala-, or [1-(13)C]Val-labeled transmembrane peptides of bacteriorhodopsin in lipid bilayers: insertion, rigid-body motions, and local conformational fluctuations at ambient temperature.	2001 Jan	11072231
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.	2001 Jan 2	11136700
Closely related HIV-1 CRF01_AE variant among injecting drug users in northern Vietnam: evidence of HIV spread across the Vietnam-China border.	2001 Jan 20	11177391
Engineering conformational flexibility in the lactose permease of Escherichia coli: use of glycine-scanning mutagenesis to rescue mutant Glu325-->Asp.	2001 Jan 23	11170394
Protein control of the redox potential of the primary quinone acceptor in reactioncCenters from Rhodobacter sphaeroides.	2001 Jan 30	11170424
Fluorescence quenching properties and chemiluminescence responses of alpha-ketothiols derivatized with o-phthalaldehyde and primary amino compounds.	2001 Jan-Feb	11180654
[Neurologic toxicity caused by zelitrex (valaciclovir) in 3 patients with renal failure. Is overdose associated with improvement of product bioavailability improvement?].	2001 Mar	11270274
Can angiotensin II receptor blockers be used in patients who have developed a cough or angioedema as a result of taking an ACE inhibitor?	2001 Mar	11263845
Early alteration in glomerular reserve in humans at genetic risk of essential hypertension: mechanisms and consequences.	2001 Mar	11244015
Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection.	2001 Mar	11231955
Purification, characterization and cloning of isovaleryl-CoA dehydrogenase from higher plant mitochondria.	2001 Mar	11231285
Isolation and characterisation of genomic and cDNA clones coding for a serine-, alanine-, and proline-rich protein of Trypanosoma cruzi.	2001 Mar	11226452
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.	2001 Mar	11226109
Ligand migration in human myoglobin: steric effects of isoleucine 107(G8) on O(2) and CO binding.	2001 Mar	11222311
Acute effects of peritoneal dialysis with dialysates containing dextrose or dextrose and amino acids on muscle protein turnover in patients with chronic renal failure.	2001 Mar	11181804
Selected Contribution: IGF-I antibody prevents increases in protein synthesis in epitrochlearis muscles from refed, diabetic rats.	2001 Mar	11181633
Influence of permeating ions on Kv1.5 channel block by nifedipine.	2001 Mar	11179060
Thrombomodulin Ala455Val polymorphism and risk of coronary heart disease.	2001 Mar 13	11245641
Acetohydroxyacid synthase: a proposed structure for regulatory subunits supported by evidence from mutagenesis.	2001 Mar 16	11243831
NMDA-responsible, APV-insensitive receptor in cultured human astrocytes.	2001 Mar 2	11270622
Mechanism of pH-dependent photolysis of aliphatic amino acids and enantiomeric enrichment of racemic leucine by circularly polarized light.	2001 Mar 22	11263916
Catalytic asymmetric coupling of 2-naphthols by chiral tridentate oxovanadium (IV) complexes.	2001 Mar 22	11263903
Kinase suppressor of Ras signals through Thr269 of c-Raf-1.	2001 Mar 30	11134016
Conversion of threonine 757 to valine enhances Stat5a transactivation potential.	2001 Mar 30	11133982
Molecular mechanism for functional interaction between DnaA protein and acidic phospholipids: identification of important amino acids.	2001 Mar 9	11102450

Patents

Sample Use Guides

In Vivo Use Guide

Valine is administered with food or as a dietary supplement.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:34:49 GMT 2025` Edited by `admin` on `Mon Mar 31 17:34:49 GMT 2025`
Record UNII	HG18B9YRS7
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

L-VALINE

Preferred Name

English

VALINE

Official Name

English

L-VALINE [JAN]

Common Name

English

valine [INN]

Common Name

English

L-VALINE [FCC]

Common Name

English

VALINE [HSDB]

Common Name

English

VALINE [USP MONOGRAPH]

Common Name

English

VALINE [MART.]

Common Name

English

LYSINE ACETATE IMPURITY D [EP IMPURITY]

Common Name

English

VALINE [VANDF]

Common Name

English

VAL

Common Name

English

NSC-76038

Code

English

VALINE [MI]

Common Name

English

VALINE [EP MONOGRAPH]

Common Name

English

L-VALINE [USP-RS]

Common Name

English

(S)-2-AMINO-3-METHYLBUTANOIC ACID

Systematic Name

English

VALINE [USAN]

Common Name

English

VALINE [II]

Common Name

English

Valine [WHO-DD]

Common Name

English

Classification Tree Code System Code

LOINC

3119-5